SANIFIT Revenue and Competitors
Estimated Revenue & Valuation
- SANIFIT's estimated annual revenue is currently $4M per year.
- SANIFIT's estimated revenue per employee is $77,500
Employee Data
- SANIFIT has 52 Employees.
- SANIFIT grew their employee count by 8% last year.
SANIFIT's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO & co-founder | Reveal Email/Phone |
SANIFIT Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is SANIFIT?
Sanifit is a biopharmaceutical company focused on the development of SNF472. The company was founded in 2007 as a spin-off of the University of the Balearic Islands and expanded its activities in the USA in 2016 with the incorporation of a subsidiary with offices in San Diego. SNF472 is an experimental drug for the treatment of cardiovascular diseases linked to calcification in the End Stage Renal Disease population undergoing haemodialysis. Sanifit has completed Phase I studies with healthy volunteers and haemodialysis patients, and after a recent series C funding round of $41.3M (?36.6M), Sanifit has launched two Phase II programs in ESRD and in the orphan space in calciphylaxis. For more information please visit www.sanifit.com
keywords:N/A
N/A
Total Funding
52
Number of Employees
$4M
Revenue (est)
8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
SANIFIT News
Smith & Nephew Plc, BSN Medical, Medtronic Plc, Amgen Inc., Laboratoris Sanifit S.L., ConvaTec Inc. The report provides a good overview of the...
Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced the completion of a €72.2 million (USD 80.9 million) total private fundraising. The financing consists of a €55.2m Series D round, led by Spain’s Caixa Cap ...
Sanifit, a Palma, Spain and San Diego, USA-based clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, closed a €72.2m ($80.9m) funding round. The financing consists of: – a €55.2m Series D round, led by Caixa Capital Risc, and – a re ...
Palma, Spain and San Diego, USA – Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced the completion of a €72.2 million (USD 80.9 million) total private fundraising. The financing consists of a €55.2m Series ...
Other Companies in Palma de Mallorca
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 52 | 18% | N/A |
#2 | $16M | 67 | N/A | N/A |
#3 | $19.8M | 78 | 24% | N/A |
#4 | N/A | 81 | 21% | N/A |
#5 | $21.1M | 83 | 77% | N/A |